Breaking News

Impax, DURECT Enter PHN Patch Pact

By Kristin Brooks | January 7, 2014

To develop and commercialize DURECT’s Eladur

Impax Laboratories and DURECT Corp. have entered an agreement granting Impax exclusive worldwide rights to develop and commercialize Eladur, DURECT’s investigational transdermal bupivacaine patch in Phase II development for the treatment of pain associated with post-herpetic neuralgia (PHN).
 
Impax will control and fund the development program. DURECT will receive $2 million upfront along with potential additional payments of as much as $61 million based on development and commercialization milestones, as well as royalties on product sales. 
 
“We’re pleased to be moving Eladur back into development through this collaboration with Impax,” said James E. Brown, president and chief executive officer of DURECT. “Existing patches used to treat PHN pain are limited by their 12-hour duration, followed by a rest period in which the patient is not to wear a patch for 12 hours. Episodes of break-through pain are frequently reported to occur during rest periods for existing patches. We share a vision with Impax to develop a patch that has the potential to reduce these episodes of break-through pain.”
 
Michael Nestor, president of Impax, said, “This agreement is another example of our commitment to building a strong brand pipeline through internal R&D and external business development. We are excited to collaborate with DURECT as this product could, if approved, fit well with the capabilities of our neurology focused specialty sales force.”

blog comments powered by Disqus
  • Cold Chain Packaging Trends

    Cold Chain Packaging Trends

    Kristin Brooks, Contract Pharma||February 4, 2016
    Susan Li of UPS discusses supply chain trends, challenges, and packaging innovations

  • Packaging Equipment Trends Preview

    Packaging Equipment Trends Preview

    Kristin Brooks, Contract Pharma||January 26, 2016
    Christian Treitel of Bosch Packaging Technology discusses trends and capabilities

  • Filings Update

    Filings Update

    December 1, 2015
    Roche, Pfizer, Janssen, BMS and more

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016